REGENXBIO Inc. | Mutual Funds
Mutual Funds that own REGENXBIO Inc.
iShares Core S&P Small Cap ETF
1,599,400
4.57%
453
0.24%
09/06/2018
Fidelity Select Biotechnology Portfolio
874,557
2.5%
-133,251
0.67%
07/31/2018
Vanguard Total Stock Market Index Fund
718,888
2.06%
0
0.01%
07/31/2018
SPDR S&P Biotech ETF
619,129
1.77%
1,593
0.75%
09/06/2018
iShares Russell 2000 ETF
598,322
1.71%
-321
0.09%
09/06/2018
FTIF SICAV - Franklin Biotechnology Discovery Fund
467,100
1.34%
-25,400
1.41%
06/30/2018
iShares Nasdaq Biotechnology ETF
409,326
1.17%
-5,355
0.28%
09/06/2018
JPMorgan Funds - Global Healthcare Fund
365,441
1.05%
-83,667
0.87%
05/31/2018
Vanguard Extended Market Index Fund
354,671
1.01%
7,400
0.04%
07/31/2018
PowerShares S&P Small Cap Health Care Portfolio
333,682
0.95%
21,219
1.88%
09/05/2018
| Address |
9600 Blackwell Road
Rockville Maryland 20850
United States
|
|
Employees
|
- |
| Website |
http://www.regenxbio.com |
| Updated |
07/08/2019 |
| REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. |
